The US homeopathic drug industry leaves too much to risk, says the Food and Drug Administration in cancelling a policy guide that linked compliance to industry standards rather than FDA approval and imposing a risk-based enforcement approach.
The agency on 24 October published a revised draft guidance for its oversight of the homeopathic industry, detailing its...